Effect of dietary and topical Celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat.
The aim of the study is to determine the effect of Celecoxib administration, dietary or topical, on expression of Ki-67, c-erb-B2, bcl-2 and bax genes in rat tongue by the immunohistochemistry methods and also tdt-mediated dupt-biotin nick end labeling assay in order to explore their role in malignant transformation and the proliferation rate, apoptosis rate in tongue squamous cell carcinoma. Effects of celecoxib on tongue carcinogenesis were investigated in 40 adult male Sprague Dawley 3-3.5 months rats initiated with 30 ppm 4-nitroquinoline-1-oxide. The immunohistochemical expression of Ki-67, bcl2, bax and c-erb-B2 were also examined for analysis of the effects of Celecoxib on tongue carcinogenesis. Differences among groups were statistically analyzed with one-way analysis of variance (SPSS-13, p < 0.05). At week 8, the incidence of tongue precancer lesions was reduced by Celecoxib and there were significant differences in the average expression of Ki-67 (p = 0.00), c-erb-B2 (p = 0.01), bax (p = 0.02), bcl2 (p = 0.02) and also in TUNEL assay (p = 0.00). The results suggest probably that the level of c-erb-B2, bcl-2 and bax expression could show behavior of squamous cell carcinoma in initiation phase of developing carcinoma.
Sohrabi
M
M
Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Kalati
F A
FA
Vatansever
S
S
Abbasi
M M
MM
Roshangar
L
L
Khaki
A A
AA
Tuglu
I M
IM
Aydemir
I
I
Dustar
Y
Y
Javadzadeh
B Y
BY
Rad
J S
JS
D000821:Animal Feed; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002273:Carcinogens; D002277:Carcinoma / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D000068579:Celecoxib; D015972:Gene Expression Regulation, Neoplastic; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D019394:Ki-67 Antigen / Q000378:metabolism*; D008297:Male; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D011720:Pyrazoles / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013449:Sulfonamides / Q000627:therapeutic use*; D014062:Tongue Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D051028:bcl-2-Associated X Protein / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002273:Carcinogens; D000068579:Celecoxib; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D011720:Pyrazoles; D018719:Erb-b2 Receptor Tyrosine Kinases; D013449:Sulfonamides; D051028:bcl-2-Associated X Protein